Dr Dan Williams
Dan Williams is CEO of SynaptixBio. After studying at the University of Dundee for a degree in biochemistry and physiology, and a PhD thereafter, he entered the industry, where he worked his way up to senior scientist. Dan then took over management of a cell research group, initially running a cell biology research project then preclinical development.
Following this he moved to drug development, focusing on the organisation and management of both manufacturing and clinical trials. Next he moved to Adaptimmune, switching from biologics to developing cell therapies. He set up development groups within Adaptimmune. While project managing some of the preclinical research and the move from the partnership with an academic group for their clinical trials, he proceeded to take on those clinical trials as a company.
He then managed the larger research group and transitioned to VP of Research Operations. From there, Dan moved to Meatable as Chief Product Officer.
Dan co-founded SynaptixBio Ltd. in 2021 with the aim to push leukodystrophy therapies through to clinical trials.
ArticleThe mother of invention: from steam engines to AI-designed drugs
Every great leap in history started with a single, urgent need. Now AI is emerging as the next great engine of invention, transforming the future of medicine faster than ever imagined.
ArticleGene silencing: a step forward for rare disease therapy
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.